31 P NMR of phospholipid metabolites in prostate cancer and benign prostatic hyperplasia

1 H MRSI in vivo is increasingly being used to diagnose prostate cancer noninvasively by measurement of the resonance from choline‐containing phospholipid metabolites. Although 31 P NMR in vivo or in vitro is potentially an excellent method for probing the phospholipid metabolites prominent in prost...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Magnetic resonance in medicine 2011-04, Vol.65 (4), p.911-913
Hauptverfasser: Komoroski, Richard A., Holder, John C., Pappas, Alex A., Finkbeiner, Alex E.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 913
container_issue 4
container_start_page 911
container_title Magnetic resonance in medicine
container_volume 65
creator Komoroski, Richard A.
Holder, John C.
Pappas, Alex A.
Finkbeiner, Alex E.
description 1 H MRSI in vivo is increasingly being used to diagnose prostate cancer noninvasively by measurement of the resonance from choline‐containing phospholipid metabolites. Although 31 P NMR in vivo or in vitro is potentially an excellent method for probing the phospholipid metabolites prominent in prostate cancer, it has been little used recently. Here, we report an in vitro 31 P NMR comparison of prostate cancer and benign prostatic hyperplasia, focusing on the levels of the major phospholipid metabolites. Unlike phosphocholine and glycerophosphocholine, phosphoethanolamine and glycerophosphoethanolamine (and their ratio) were significantly different between cancer and benign prostatic hyperplasia. The high level of phosphoethanolamine+glycerophosphoethanolamine relative to phosphocholine+glycerophosphocholine suggests that the former may be significant contributors to the “total choline” resonance observed by 1 H MRSI in vivo. Magn Reson Med, 2010. © 2010 Wiley‐Liss, Inc.
doi_str_mv 10.1002/mrm.22677
format Article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1002_mrm_22677</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1002_mrm_22677</sourcerecordid><originalsourceid>FETCH-LOGICAL-c747-67c6f61e3955b1298cfe954f27b1d42e4c38577918c4e91dab6a5f492049a32b3</originalsourceid><addsrcrecordid>eNo9kMlKBDEYhIMo2I4efINcPfSYPZ2jDG4wLsgcvDVJ-o8T6SUkfZm3t13wUFRBQVF8CF1SsqaEsOshD2vGlNZHqKKSsZpJI45RRbQgNadGnKKzUj4JIcZoUaF3TvErfn56w1PAaT-VRX1MscMDzNYteYaC44hTnspsZ8Dejh4ytmOHHYzx47-KHu8PCXLqbYn2HJ0E2xe4-PMV2t3d7jYP9fbl_nFzs629FrpW2qugKHAjpaPMND6AkSIw7WgnGAjPG6m1oY0XYGhnnbIyCMOIMJYzx1fo6nfWLydKhtCmHAebDy0l7TeRdiHS_hDhX4vsU_A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>31 P NMR of phospholipid metabolites in prostate cancer and benign prostatic hyperplasia</title><source>Access via Wiley Online Library</source><source>Wiley Online Library (Open Access Collection)</source><creator>Komoroski, Richard A. ; Holder, John C. ; Pappas, Alex A. ; Finkbeiner, Alex E.</creator><creatorcontrib>Komoroski, Richard A. ; Holder, John C. ; Pappas, Alex A. ; Finkbeiner, Alex E.</creatorcontrib><description>1 H MRSI in vivo is increasingly being used to diagnose prostate cancer noninvasively by measurement of the resonance from choline‐containing phospholipid metabolites. Although 31 P NMR in vivo or in vitro is potentially an excellent method for probing the phospholipid metabolites prominent in prostate cancer, it has been little used recently. Here, we report an in vitro 31 P NMR comparison of prostate cancer and benign prostatic hyperplasia, focusing on the levels of the major phospholipid metabolites. Unlike phosphocholine and glycerophosphocholine, phosphoethanolamine and glycerophosphoethanolamine (and their ratio) were significantly different between cancer and benign prostatic hyperplasia. The high level of phosphoethanolamine+glycerophosphoethanolamine relative to phosphocholine+glycerophosphocholine suggests that the former may be significant contributors to the “total choline” resonance observed by 1 H MRSI in vivo. Magn Reson Med, 2010. © 2010 Wiley‐Liss, Inc.</description><identifier>ISSN: 0740-3194</identifier><identifier>EISSN: 1522-2594</identifier><identifier>DOI: 10.1002/mrm.22677</identifier><language>eng</language><ispartof>Magnetic resonance in medicine, 2011-04, Vol.65 (4), p.911-913</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c747-67c6f61e3955b1298cfe954f27b1d42e4c38577918c4e91dab6a5f492049a32b3</citedby><cites>FETCH-LOGICAL-c747-67c6f61e3955b1298cfe954f27b1d42e4c38577918c4e91dab6a5f492049a32b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Komoroski, Richard A.</creatorcontrib><creatorcontrib>Holder, John C.</creatorcontrib><creatorcontrib>Pappas, Alex A.</creatorcontrib><creatorcontrib>Finkbeiner, Alex E.</creatorcontrib><title>31 P NMR of phospholipid metabolites in prostate cancer and benign prostatic hyperplasia</title><title>Magnetic resonance in medicine</title><description>1 H MRSI in vivo is increasingly being used to diagnose prostate cancer noninvasively by measurement of the resonance from choline‐containing phospholipid metabolites. Although 31 P NMR in vivo or in vitro is potentially an excellent method for probing the phospholipid metabolites prominent in prostate cancer, it has been little used recently. Here, we report an in vitro 31 P NMR comparison of prostate cancer and benign prostatic hyperplasia, focusing on the levels of the major phospholipid metabolites. Unlike phosphocholine and glycerophosphocholine, phosphoethanolamine and glycerophosphoethanolamine (and their ratio) were significantly different between cancer and benign prostatic hyperplasia. The high level of phosphoethanolamine+glycerophosphoethanolamine relative to phosphocholine+glycerophosphocholine suggests that the former may be significant contributors to the “total choline” resonance observed by 1 H MRSI in vivo. Magn Reson Med, 2010. © 2010 Wiley‐Liss, Inc.</description><issn>0740-3194</issn><issn>1522-2594</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNo9kMlKBDEYhIMo2I4efINcPfSYPZ2jDG4wLsgcvDVJ-o8T6SUkfZm3t13wUFRBQVF8CF1SsqaEsOshD2vGlNZHqKKSsZpJI45RRbQgNadGnKKzUj4JIcZoUaF3TvErfn56w1PAaT-VRX1MscMDzNYteYaC44hTnspsZ8Dejh4ytmOHHYzx47-KHu8PCXLqbYn2HJ0E2xe4-PMV2t3d7jYP9fbl_nFzs629FrpW2qugKHAjpaPMND6AkSIw7WgnGAjPG6m1oY0XYGhnnbIyCMOIMJYzx1fo6nfWLydKhtCmHAebDy0l7TeRdiHS_hDhX4vsU_A</recordid><startdate>201104</startdate><enddate>201104</enddate><creator>Komoroski, Richard A.</creator><creator>Holder, John C.</creator><creator>Pappas, Alex A.</creator><creator>Finkbeiner, Alex E.</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201104</creationdate><title>31 P NMR of phospholipid metabolites in prostate cancer and benign prostatic hyperplasia</title><author>Komoroski, Richard A. ; Holder, John C. ; Pappas, Alex A. ; Finkbeiner, Alex E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c747-67c6f61e3955b1298cfe954f27b1d42e4c38577918c4e91dab6a5f492049a32b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Komoroski, Richard A.</creatorcontrib><creatorcontrib>Holder, John C.</creatorcontrib><creatorcontrib>Pappas, Alex A.</creatorcontrib><creatorcontrib>Finkbeiner, Alex E.</creatorcontrib><collection>CrossRef</collection><jtitle>Magnetic resonance in medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Komoroski, Richard A.</au><au>Holder, John C.</au><au>Pappas, Alex A.</au><au>Finkbeiner, Alex E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>31 P NMR of phospholipid metabolites in prostate cancer and benign prostatic hyperplasia</atitle><jtitle>Magnetic resonance in medicine</jtitle><date>2011-04</date><risdate>2011</risdate><volume>65</volume><issue>4</issue><spage>911</spage><epage>913</epage><pages>911-913</pages><issn>0740-3194</issn><eissn>1522-2594</eissn><abstract>1 H MRSI in vivo is increasingly being used to diagnose prostate cancer noninvasively by measurement of the resonance from choline‐containing phospholipid metabolites. Although 31 P NMR in vivo or in vitro is potentially an excellent method for probing the phospholipid metabolites prominent in prostate cancer, it has been little used recently. Here, we report an in vitro 31 P NMR comparison of prostate cancer and benign prostatic hyperplasia, focusing on the levels of the major phospholipid metabolites. Unlike phosphocholine and glycerophosphocholine, phosphoethanolamine and glycerophosphoethanolamine (and their ratio) were significantly different between cancer and benign prostatic hyperplasia. The high level of phosphoethanolamine+glycerophosphoethanolamine relative to phosphocholine+glycerophosphocholine suggests that the former may be significant contributors to the “total choline” resonance observed by 1 H MRSI in vivo. Magn Reson Med, 2010. © 2010 Wiley‐Liss, Inc.</abstract><doi>10.1002/mrm.22677</doi><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0740-3194
ispartof Magnetic resonance in medicine, 2011-04, Vol.65 (4), p.911-913
issn 0740-3194
1522-2594
language eng
recordid cdi_crossref_primary_10_1002_mrm_22677
source Access via Wiley Online Library; Wiley Online Library (Open Access Collection)
title 31 P NMR of phospholipid metabolites in prostate cancer and benign prostatic hyperplasia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T21%3A28%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=31%20P%20NMR%20of%20phospholipid%20metabolites%20in%20prostate%20cancer%20and%20benign%20prostatic%20hyperplasia&rft.jtitle=Magnetic%20resonance%20in%20medicine&rft.au=Komoroski,%20Richard%20A.&rft.date=2011-04&rft.volume=65&rft.issue=4&rft.spage=911&rft.epage=913&rft.pages=911-913&rft.issn=0740-3194&rft.eissn=1522-2594&rft_id=info:doi/10.1002/mrm.22677&rft_dat=%3Ccrossref%3E10_1002_mrm_22677%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true